158 related articles for article (PubMed ID: 32697773)
1. Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study.
Zhou H; Zhu M; Ma L; Zhou J; Dong B; Zhang G; Cen S; Wang Y; Wang J
PLoS One; 2020; 15(7):e0235483. PubMed ID: 32697773
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants.
Zhu M; Zhou H; Ma L; Dong B; Zhou J; Zhang G; Wang M; Wang J; Cen S; Wang Y
Eur J Med Chem; 2021 Aug; 220():113450. PubMed ID: 33906049
[TBL] [Abstract][Full Text] [Related]
3. Rational design, synthesis and biological evaluation of novel HIV-1 protease inhibitors containing 2-phenylacetamide derivatives as P2 ligands with potent activity against DRV-Resistant HIV-1 variants.
Meng S; Gao Y; Qiang G; Hu Z; Shan Q; Wang J; Wang Y; Mou J
Bioorg Med Chem Lett; 2024 Mar; 101():129651. PubMed ID: 38342391
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
Ghosh AK; Fyvie WS; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
ChemMedChem; 2017 Dec; 12(23):1942-1952. PubMed ID: 29110408
[TBL] [Abstract][Full Text] [Related]
5. Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite.
Zhu M; Ma L; Dong B; Zhang G; Wang J; Zhou J; Cen S; Wang Y
Bioorg Med Chem; 2020 Aug; 28(16):115623. PubMed ID: 32690263
[TBL] [Abstract][Full Text] [Related]
6. Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
Ghosh AK; Rao KV; Nyalapatla PR; Osswald HL; Martyr CD; Aoki M; Hayashi H; Agniswamy J; Wang YF; Bulut H; Das D; Weber IT; Mitsuya H
J Med Chem; 2017 May; 60(10):4267-4278. PubMed ID: 28418652
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
Zhu M; Du XN; Li YG; Zhang GN; Wang JX; Wang YC
Bioorg Med Chem Lett; 2019 Feb; 29(3):357-361. PubMed ID: 30580917
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
[TBL] [Abstract][Full Text] [Related]
9. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1' ligand.
Dou Y; Zhu M; Dong B; Wang JX; Zhang GN; Zhang F; Wang YC
Bioorg Med Chem Lett; 2020 Apr; 30(7):127019. PubMed ID: 32057582
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
Ghosh AK; R Nyalapatla P; Kovela S; Rao KV; Brindisi M; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2018 May; 61(10):4561-4577. PubMed ID: 29763303
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.
Ghosh AK; Yu X; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
J Med Chem; 2015 Jul; 58(13):5334-43. PubMed ID: 26107245
[TBL] [Abstract][Full Text] [Related]
13. Novel Protease Inhibitors Containing C-5-Modified
Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
[TBL] [Abstract][Full Text] [Related]
15. Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.
Ghosh AK; Xia Z; Kovela S; Robinson WL; Johnson ME; Kneller DW; Wang YF; Aoki M; Takamatsu Y; Weber IT; Mitsuya H
ChemMedChem; 2019 Nov; 14(21):1863-1872. PubMed ID: 31549492
[TBL] [Abstract][Full Text] [Related]
16. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
Ghosh AK; Xu CX; Rao KV; Baldridge A; Agniswamy J; Wang YF; Weber IT; Aoki M; Miguel SG; Amano M; Mitsuya H
ChemMedChem; 2010 Nov; 5(11):1850-4. PubMed ID: 20827746
[No Abstract] [Full Text] [Related]
17. Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
Ghosh AK; Kovela S; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2020 May; 63(9):4867-4879. PubMed ID: 32348139
[TBL] [Abstract][Full Text] [Related]
18. Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.
Ghosh AK; Brindisi M; Nyalapatla PR; Takayama J; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem; 2017 Oct; 25(19):5114-5127. PubMed ID: 28434781
[TBL] [Abstract][Full Text] [Related]
19. Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors (II).
Hohlfeld K; Wegner JK; Kesteleyn B; Linclau B; Unge J
J Med Chem; 2015 May; 58(9):4029-38. PubMed ID: 25897791
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
Reddy GS; Ali A; Nalam MN; Anjum SG; Cao H; Nathans RS; Schiffer CA; Rana TM
J Med Chem; 2007 Sep; 50(18):4316-28. PubMed ID: 17696512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]